Numerous comments on a Facebook group called “Dexcom G7 – Issues and Complaints” has brought to light a problem that users are referring to as “goose necking.” MD+DI learned more about this issue – ...
June 6 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab said the use of its continuous glucose monitor, G7, led to improved blood sugar control in patients with type 2 diabetes not ...
The Dexcom 15-day G7 continuous glucose monitor (CGM) is accurate and safe for use up to 15.5 days in adults with diabetes. Currently under review by the US Food and Drug Administration, it is more ...
This combined sensor-transmitter continuous glucose monitor (CGM) technology offers glucose values every 5 minutes. Sensors last for up to 10-15 days and provide alerts for high and low blood sugars ...
Dexcom sponsored CONNECT randomized controlled trial expected to help establish new standard of care for CGM use by people with Type 2 diabetes not using insulin around the world. Showed use of Dexcom ...
Dexcom anticipates that the findings could drive a shift in the standard of care for type 2 diabetes patients who do not use ...
DexCom, Inc. DXCM recently announced positive results from its CONNECT randomized controlled trial, demonstrating that use of the Dexcom G7 continuous glucose monitoring (CGM) system significantly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results